Speaker illustration

Doctor Marc Evans

Cardiff (United Kingdom of Great Britain & Northern Ireland)

Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Medical management and risk factors

Thumbnail

This platform is supported by

logo Novo Nordisk